Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Intranasal Epinastine in Healthy Male Volunteers
NCT02260037Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2001
- Primary completion
- Sep 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in allergic rhinitis (AR) comparing Epinastine nasal with Placebo (2 arms). Primary endpoints: Number of patients with clinically relevant findings in vital signs, Number of patients with clinically relevant findings in 12-lead ECG and 3 more. Started Aug 2001; status: completed.
02
Drugs
epinastine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02260037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260037.